Vero Biotech Inc.
ATLANTA, GA · Founded 2006 · CIK 0001359620 · Biotech · Private
GENOSYL DS, a molecular diagnostic system for life sciences applications
vero-biotech.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $84M
- 6 Form D · Dec 2021
- 58 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 21 granted · 19 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20082010201220142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised· 1 of 2 same day | Form D · SEC | $2,136,030 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $2,136,030 | |
| Private capital raised | Form D · SEC | $7,990,819 | |
| Private capital raised | Form D · SEC | $14,570,606 | |
| Private capital raised | Form D · SEC | $29,941,000 | |
| Private capital raised | Form D · SEC | $27,265,773 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1943 | Sparrow Pharmaceuticals | — | $73M |
| 1944 | Iviva Medical | — | $2.0M |
| 1945 | PanTheryx, Inc. | — | $84M |
| 1946 | Vero Biotech Inc. | — | $84M |
| 1947 | RAKTA THERAPEUTICS, INC. | — | — |
| 1948 | IGF Oncology, LLC | — | $2.4M |
| 1949 | GENECENTRIX INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Paul AntinoriExecutive Officer
- Eric BednarskiDirector
- Todd BradyDirector
- Roberto CohenExecutive Officer
- Kurt DasseDirector · Executive Officer
- David FineDirector · Executive Officer
- David Fine, Ph.D.Director · Executive Officer
- Brent FurseDirector · Executive Officer
- T. Johnson, M.D.Director
- Anthony LoumidisExecutive Officer
- Theo Melas-KyriaziDirector
- James O'BrienDirector · Executive Officer
- Vinzenz PloererDirector
- Robert RoscignoExecutive Officer
- Daniel SalazarDirector
- Dan Salazar, Ph.D.Director
- Steven ShulmanDirector · Executive Officer
- Tod ShultzExecutive Officer
- Thiago TavaresDirector
- Shasha ZouExecutive Officer
Patents
- Systems, Methods, And Apparatus For Producing Nitric Oxideapplication
- Conversion Of Nitrogen Dioxide (NO2) To Nitric Oxide (no)granted
- Nitric Oxide Therapiesgranted
- Systems, Methods, And Apparatus For Producing Nitric Oxideapplication
- Delivery Of Ultra Pure Nitric Oxide (no)granted
- Systems, Methods, And Apparatus For Producing Nitric Oxideapplication
- Start-up Protocols For Nitric Oxide Delivery Devicegranted
- Method And Apparatus For Calibration Of Gas And Liquid Concentration Sensors Without The Need For Known Calibration Standardsapplication
- Method And Apparatus For Calibration Of Gas And Liquid Concentration Sensors Without The Need For Known Calibration Standardsgranted
- Systems, Methods, And Apparatus For Producing Nitric Oxideapplication
- Systems, Methods, And Apparatus For Producing Nitric Oxideapplication
- Systems And Devices For Generating Nitric Oxideapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.